Bank of New York Mellon Corp lowered its position in Integra Lifesciences Holdings Corp (NASDAQ:IART) by 0.1% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 738,154 shares of the life sciences company’s stock after selling 1,015 shares during the period. Bank of New York Mellon Corp’s holdings in Integra Lifesciences were worth $35,328,000 at the end of the most recent quarter.
A number of other hedge funds have also recently made changes to their positions in the business. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Integra Lifesciences by 38.3% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,806 shares of the life sciences company’s stock worth $182,000 after acquiring an additional 1,054 shares during the last quarter. Zions Bancorporation acquired a new stake in shares of Integra Lifesciences in the 3rd quarter worth $205,000. Campbell Newman Asset Management Inc. increased its stake in shares of Integra Lifesciences by 21.5% in the 4th quarter. Campbell Newman Asset Management Inc. now owns 6,964 shares of the life sciences company’s stock worth $333,000 after acquiring an additional 1,234 shares during the last quarter. Oppenheimer & Co. Inc. increased its stake in shares of Integra Lifesciences by 25.2% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 7,293 shares of the life sciences company’s stock worth $368,000 after acquiring an additional 1,466 shares during the last quarter. Finally, Pacer Advisors Inc. increased its stake in shares of Integra Lifesciences by 23.0% in the 3rd quarter. Pacer Advisors Inc. now owns 7,672 shares of the life sciences company’s stock worth $387,000 after acquiring an additional 1,436 shares during the last quarter. Institutional investors own 90.93% of the company’s stock.
In related news, VP Joseph Vinhais sold 6,800 shares of the firm’s stock in a transaction dated Friday, March 9th. The stock was sold at an average price of $54.13, for a total transaction of $368,084.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Richard E. Caruso sold 32,880 shares of the firm’s stock in a transaction dated Thursday, March 8th. The shares were sold at an average price of $53.68, for a total value of $1,764,998.40. The disclosure for this sale can be found here. Insiders have sold a total of 70,996 shares of company stock valued at $3,822,267 over the last three months. Corporate insiders own 21.50% of the company’s stock.
Shares of Integra Lifesciences Holdings Corp (NASDAQ:IART) opened at $56.23 on Wednesday. The company has a current ratio of 2.36, a quick ratio of 1.51 and a debt-to-equity ratio of 1.85. The stock has a market capitalization of $4,305.41, a PE ratio of 68.57, a P/E/G ratio of 1.69 and a beta of 0.65. Integra Lifesciences Holdings Corp has a 52-week low of $40.51 and a 52-week high of $56.42.
Integra Lifesciences (NASDAQ:IART) last issued its quarterly earnings data on Tuesday, February 27th. The life sciences company reported $0.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.56 by $0.08. The firm had revenue of $368.60 million during the quarter, compared to the consensus estimate of $362.64 million. Integra Lifesciences had a return on equity of 16.94% and a net margin of 5.45%. The company’s quarterly revenue was up 44.2% on a year-over-year basis. During the same period last year, the company earned $0.52 EPS. analysts predict that Integra Lifesciences Holdings Corp will post 2.33 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This news story was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this news story can be accessed at https://sportsperspectives.com/2018/03/14/bank-of-new-york-mellon-corp-decreases-holdings-in-integra-lifesciences-holdings-corp-iart.html.
Integra Lifesciences Profile
Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.
Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra Lifesciences Holdings Corp (NASDAQ:IART).
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.